Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 561

1.

Cardiac Remodeling in Chronic Kidney Disease.

Kaesler N, Babler A, Floege J, Kramann R.

Toxins (Basel). 2020 Mar 5;12(3). pii: E161. doi: 10.3390/toxins12030161. Review.

2.

Cellular and Molecular Mechanisms of Kidney Injury in 2,8-Dihydroxyadenine Nephropathy.

Klinkhammer BM, Djudjaj S, Kunter U, Palsson R, Edvardsson VO, Wiech T, Thorsteinsdottir M, Hardarson S, Foresto-Neto O, Mulay SR, Moeller MJ, Jahnen-Dechent W, Floege J, Anders HJ, Boor P.

J Am Soc Nephrol. 2020 Feb 21. pii: ASN.2019080827. doi: 10.1681/ASN.2019080827. [Epub ahead of print]

PMID:
32086278
3.

Microvasculopathy and soft tissue calcification in mice are governed by fetuin-A, magnesium and pyrophosphate.

Babler A, Schmitz C, Buescher A, Herrmann M, Gremse F, Gorgels T, Floege J, Jahnen-Dechent W.

PLoS One. 2020 Feb 19;15(2):e0228938. doi: 10.1371/journal.pone.0228938. eCollection 2020.

4.

The nucleic acid binding protein YB-1-controlled expression of CXCL-1 modulates kidney damage in liver fibrosis.

Hermert D, Martin IV, Reiss LK, Liu X, Breitkopf DM, Reimer KC, Alidousty C, Rauen T, Floege J, Ostendorf T, Weiskirchen R, Raffetseder U.

Kidney Int. 2020 Apr;97(4):741-752. doi: 10.1016/j.kint.2019.10.024. Epub 2019 Nov 9.

PMID:
32061437
5.

A Functional Landscape of CKD Entities From Public Transcriptomic Data.

Tajti F, Kuppe C, Antoranz A, Ibrahim MM, Kim H, Ceccarelli F, Holland CH, Olauson H, Floege J, Alexopoulos LG, Kramann R, Saez-Rodriguez J.

Kidney Int Rep. 2019 Nov 13;5(2):211-224. doi: 10.1016/j.ekir.2019.11.005. eCollection 2020 Feb.

6.

Dysregulated mesenchymal PDGFR-β drives kidney fibrosis.

Buhl EM, Djudjaj S, Klinkhammer BM, Ermert K, Puelles VG, Lindenmeyer MT, Cohen CD, He C, Borkham-Kamphorst E, Weiskirchen R, Denecke B, Trairatphisan P, Saez-Rodriguez J, Huber TB, Olson LE, Floege J, Boor P.

EMBO Mol Med. 2020 Mar 6;12(3):e11021. doi: 10.15252/emmm.201911021. Epub 2020 Jan 14.

7.

Cardiovascular disease in patients with chronic kidney disease.

Saritas T, Floege J.

Herz. 2020 Apr;45(2):122-128. doi: 10.1007/s00059-019-04884-0.

PMID:
31938803
8.

The YB-1:Notch-3 axis modulates immune cell responses and organ damage in systemic lupus erythematosus.

Breitkopf DM, Jankowski V, Ohl K, Hermann J, Hermert D, Tenbrock K, Liu X, Martin IV, Wang J, Groll F, Gröne E, Floege J, Ostendorf T, Rauen T, Raffetseder U.

Kidney Int. 2020 Feb;97(2):289-303. doi: 10.1016/j.kint.2019.09.031. Epub 2019 Oct 30.

PMID:
31882173
9.

Phosphate binders in chronic kidney disease: an updated narrative review of recent data.

Floege J.

J Nephrol. 2019 Dec 21. doi: 10.1007/s40620-019-00689-w. [Epub ahead of print] Review.

PMID:
31865608
10.

Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes.

Louie KS, Erhard C, Wheeler DC, Stenvinkel P, Fouqueray B, Floege J.

J Nephrol. 2019 Dec 17. doi: 10.1007/s40620-019-00686-z. [Epub ahead of print]

PMID:
31848883
11.

Trends of renal diseases in Germany: review of a regional renal biopsy database from 1990 to 2013.

Zink CM, Ernst S, Riehl J, Helmchen U, Gröne HJ, Floege J, Schlieper G.

Clin Kidney J. 2019 Mar 18;12(6):795-800. doi: 10.1093/ckj/sfz023. eCollection 2019 Dec.

12.

A collagen-binding protein enables molecular imaging of kidney fibrosis in vivo.

Baues M, Klinkhammer BM, Ehling J, Gremse F, van Zandvoort MAMJ, Reutelingsperger CPM, Daniel C, Amann K, Bábíčková J, Kiessling F, Floege J, Lammers T, Boor P.

Kidney Int. 2020 Mar;97(3):609-614. doi: 10.1016/j.kint.2019.08.029. Epub 2019 Sep 18.

PMID:
31784048
13.

Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study.

Djuric P, Dimkovic N, Schlieper G, Djuric Z, Pantelic M, Mitrovic M, Jankovic A, Milanov M, Kuzmanovic Pficer J, Floege J.

Nephrol Dial Transplant. 2020 Jan 1;35(1):162-169. doi: 10.1093/ndt/gfz204.

PMID:
31764989
14.

Association Between Dietary Patterns and Kidney Function in Patients With Chronic Kidney Disease: A Cross-Sectional Analysis of the German Chronic Kidney Disease Study.

Heindel J, Baid-Agrawal S, Rebholz CM, Nadal J, Schmid M, Schaeffner E, Schneider MP, Meiselbach H, Kaesler N, Bergmann M, Ernst S, Krane V, Eckardt KU, Floege J, Schlieper G, Saritas T; GCKD Study Investigators.

J Ren Nutr. 2019 Nov 21. pii: S1051-2276(19)30347-4. doi: 10.1053/j.jrn.2019.09.008. [Epub ahead of print]

PMID:
31761711
15.

The authors reply.

Saez-Rodriguez J, Rinschen MM, Floege J, Kramann R.

Kidney Int. 2019 Dec;96(6):1422-1423. doi: 10.1016/j.kint.2019.09.011. No abstract available.

PMID:
31759488
16.

Cre recombinase toxicity in podocytes: a novel genetic model for FSGS in adolescent mice.

Frahsek M, Schulte K, Chia-Gil A, Djudjaj S, Schueler H, Leuchtle K, Smeets B, Dijkman H, Floege J, Moeller MJ.

Am J Physiol Renal Physiol. 2019 Nov 1;317(5):F1375-F1382. doi: 10.1152/ajprenal.00573.2018. Epub 2019 Oct 7.

PMID:
31588799
17.

A new tool to predict the risk of progression in IgA nephropathy.

Floege J.

Kidney Int. 2019 Oct;96(4):808-809. doi: 10.1016/j.kint.2019.07.009. Epub 2019 Aug 1. No abstract available.

PMID:
31471162
18.

Speckle Tracking Echocardiography and All-Cause and Cardiovascular Mortality Risk in Chronic Kidney Disease Patients.

Jahn L, Kramann R, Marx N, Floege J, Becker M, Schlieper G.

Kidney Blood Press Res. 2019;44(4):690-703. doi: 10.1159/000501225. Epub 2019 Aug 15.

19.

A Novel Role for GATA3 in Mesangial Cells in Glomerular Development and Injury.

Grigorieva IV, Oszwald A, Grigorieva EF, Schachner H, Neudert B, Ostendorf T, Floege J, Lindenmeyer MT, Cohen CD, Panzer U, Aigner C, Schmidt A, Grosveld F, Thakker RV, Rees AJ, Kain R.

J Am Soc Nephrol. 2019 Sep;30(9):1641-1658. doi: 10.1681/ASN.2018111143. Epub 2019 Aug 12.

PMID:
31405951
20.

Non-invasive evaluation of coronary heart disease in patients with chronic kidney disease using photoplethysmography.

Saritas T, Greber R, Venema B, Puelles VG, Ernst S, Blazek V, Floege J, Leonhardt S, Schlieper G.

Clin Kidney J. 2019 Jan 25;12(4):538-545. doi: 10.1093/ckj/sfy135. eCollection 2019 Aug.

21.

[Science as a cornerstone of medical education and training].

Floege J, Gamstätter T.

Dtsch Med Wochenschr. 2019 Aug;144(15):1005. doi: 10.1055/a-0870-6560. Epub 2019 Jul 26. German. No abstract available.

PMID:
31350738
22.

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.

Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, Simon AL, Ying J, Beck GJ, Wanner C, Floege J, Li PK, Perkovic V, Vonesh EF, Greene T.

J Am Soc Nephrol. 2019 Sep;30(9):1735-1745. doi: 10.1681/ASN.2019010007. Epub 2019 Jul 10.

PMID:
31292197
23.

High-fat diet-induced obesity causes an inflammatory microenvironment in the kidneys of aging Long-Evans rats.

Laurentius T, Raffetseder U, Fellner C, Kob R, Nourbakhsh M, Floege J, Bertsch T, Bollheimer LC, Ostendorf T.

J Inflamm (Lond). 2019 Jun 25;16:14. doi: 10.1186/s12950-019-0219-x. eCollection 2019.

24.

Evaluation of Electrocardiographic Parameters Predicting Cardiovascular Events in Patients with End-Stage Renal Disease before and after Transplantation.

Buerschaper L, Floege J, Mühlfeld A, Schlieper G.

Kidney Blood Press Res. 2019;44(4):615-627. doi: 10.1159/000500917. Epub 2019 Jun 26.

25.

Fatal Attraction: Immunoglobulin A and the Glomerular Mesangium.

Floege J.

J Am Soc Nephrol. 2019 Jul;30(7):1139-1141. doi: 10.1681/ASN.2019040373. Epub 2019 Jun 21. No abstract available.

PMID:
31227635
26.

Novel 3D analysis using optical tissue clearing documents the evolution of murine rapidly progressive glomerulonephritis.

Puelles VG, Fleck D, Ortz L, Papadouri S, Strieder T, Böhner AMC, van der Wolde JW, Vogt M, Saritas T, Kuppe C, Fuss A, Menzel S, Klinkhammer BM, Müller-Newen G, Heymann F, Decker L, Braun F, Kretz O, Huber TB, Susaki EA, Ueda HR, Boor P, Floege J, Kramann R, Kurts C, Bertram JF, Spehr M, Nikolic-Paterson DJ, Moeller MJ.

Kidney Int. 2019 Aug;96(2):505-516. doi: 10.1016/j.kint.2019.02.034. Epub 2019 Mar 15.

27.

Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease.

Carter SA, Lightstone L, Cattran D, Bagga A, Barbour SJ, Barratt J, Boletis J, Caster D, Coppo R, Fervenza FC, Floege J, Hladunewich M, Hogan JJ, Kitching AR, Lafayette R, Malvar A, Radhakrishnan J, Rovin BH, Zhang H, Gutman T, Howell M, Logeman C, Shen JI, Teixeira-Pinto A, Alexander SI, Cho Y, Craig JC, Harris D, Johnson DW, Kerr PG, Ryan J, Viecelli AK, Wang AY, Wilkie M, Scholes-Robertson N, Tong A; SONG-GD Initiative.

Kidney Int. 2019 Jun;95(6):1280-1283. doi: 10.1016/j.kint.2019.01.047. No abstract available.

PMID:
31122702
28.

Novel parietal epithelial cell subpopulations contribute to focal segmental glomerulosclerosis and glomerular tip lesions.

Kuppe C, Leuchtle K, Wagner A, Kabgani N, Saritas T, Puelles VG, Smeets B, Hakroush S, van der Vlag J, Boor P, Schiffer M, Gröne HJ, Fogo A, Floege J, Moeller MJ.

Kidney Int. 2019 Jul;96(1):80-93. doi: 10.1016/j.kint.2019.01.037. Epub 2019 Feb 27.

29.

Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort.

Lamina C, Kronenberg F, Stenvinkel P, Froissart M, Forer L, Schönherr S, Wheeler DC, Eckardt KU, Floege J.

Nephrol Dial Transplant. 2020 Mar 1;35(3):478-487. doi: 10.1093/ndt/gfz060.

PMID:
31006013
30.

Antimalarials in IgA Nephropathy: Did Our Supportive Therapy Armamentarium Just Increase?

Floege J.

Am J Kidney Dis. 2019 Jul;74(1):6-8. doi: 10.1053/j.ajkd.2019.02.022. Epub 2019 Apr 18. No abstract available.

PMID:
31005372
31.

Big science and big data in nephrology.

Saez-Rodriguez J, Rinschen MM, Floege J, Kramann R.

Kidney Int. 2019 Jun;95(6):1326-1337. doi: 10.1016/j.kint.2018.11.048. Epub 2019 Mar 5. Review.

32.

Elastin imaging enables noninvasive staging and treatment monitoring of kidney fibrosis.

Sun Q, Baues M, Klinkhammer BM, Ehling J, Djudjaj S, Drude NI, Daniel C, Amann K, Kramann R, Kim H, Saez-Rodriguez J, Weiskirchen R, Onthank DC, Botnar RM, Kiessling F, Floege J, Lammers T, Boor P.

Sci Transl Med. 2019 Apr 3;11(486). pii: eaat4865. doi: 10.1126/scitranslmed.aat4865.

PMID:
30944168
33.

[Immunoglobulin A nephropathy].

Seikrit C, Rauen T, Floege J.

Internist (Berl). 2019 May;60(5):432-439. doi: 10.1007/s00108-019-0588-5. Review. German.

PMID:
30895344
34.

Disruption of CUL3-mediated ubiquitination causes proximal tubule injury and kidney fibrosis.

Saritas T, Cuevas CA, Ferdaus MZ, Kuppe C, Kramann R, Moeller MJ, Floege J, Singer JD, McCormick JA.

Sci Rep. 2019 Mar 14;9(1):4596. doi: 10.1038/s41598-019-40795-0.

35.

Identification of platelet-derived growth factor C as a mediator of both renal fibrosis and hypertension.

van Roeyen CRC, Martin IV, Drescher A, Schuett KA, Hermert D, Raffetseder U, Otten S, Buhl EM, Braun GS, Kuppe C, Liehn E, Boor P, Weiskirchen R, Eriksson U, Gross O, Eitner F, Floege J, Ostendorf T.

Kidney Int. 2019 May;95(5):1103-1119. doi: 10.1016/j.kint.2018.11.031. Epub 2019 Feb 28.

PMID:
30827511
36.

Left Ventricular Structure in Patients With Mild-to-Moderate CKD-a Magnetic Resonance Imaging Study.

Schneider MP, Scheppach JB, Raff U, Toncar S, Ritter C, Klink T, Störk S, Wanner C, Schlieper G, Saritas T, Reinartz SD, Floege J, Friedrich N, Janka R, Uder M, Schmieder RE, Eckardt KU.

Kidney Int Rep. 2018 Oct 11;4(2):267-274. doi: 10.1016/j.ekir.2018.10.004. eCollection 2019 Feb.

37.

Magnesium but not nicotinamide prevents vascular calcification in experimental uraemia.

Kaesler N, Goettsch C, Weis D, Schurgers L, Hellmann B, Floege J, Kramann R.

Nephrol Dial Transplant. 2020 Jan 1;35(1):65-73. doi: 10.1093/ndt/gfy410.

PMID:
30715488
38.

[Perspectives 2025 - Positions of the German Society of Internal Medicine].

Vogelmeier C, Floege J, Gamstätter T.

Dtsch Med Wochenschr. 2019 Feb;144(3):207-212. doi: 10.1055/a-0799-5146. Epub 2019 Jan 31. German.

PMID:
30703843
39.

Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, Roccatello D, Cheung M, Wheeler DC, Winkelmayer WC, Floege J; Conference Participants.

Kidney Int. 2019 Feb;95(2):281-295. doi: 10.1016/j.kint.2018.11.008.

40.

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, Wetzels JFM, Cheung M, Wheeler DC, Winkelmayer WC, Rovin BH; Conference Participants.

Kidney Int. 2019 Feb;95(2):268-280. doi: 10.1016/j.kint.2018.10.018.

PMID:
30665568
41.

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.

Thompson A, Carroll K, A Inker L, Floege J, Perkovic V, Boyer-Suavet S, W Major R, I Schimpf J, Barratt J, Cattran DC, S Gillespie B, Kausz A, W Mercer A, Reich HN, H Rovin B, West M, Nachman PH.

Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481. doi: 10.2215/CJN.08600718. Epub 2019 Jan 11.

42.

Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores).

Schimpf JI, Klein T, Fitzner C, Eitner F, Porubsky S, Hilgers RD, Floege J, Groene HJ, Rauen T.

BMC Nephrol. 2018 Nov 19;19(1):328. doi: 10.1186/s12882-018-1128-6.

43.

Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.

Coppo R, D'Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, Cattran D, Cook TH, Feehally J, Tesar V, Maixnerova D, Peruzzi L, Amore A, Lundberg S, Di Palma AM, Gesualdo L, Emma F, Rollino C, Praga M, Biancone L, Pani A, Feriozzi S, Polci R, Barratt J, Del Vecchio L, Locatelli F, Pierucci A, Caliskan Y, Perkowska-Ptasinska A, Durlik M, Moggia E, Ballarin JC, Wetzels JFM, Goumenos D, Papasotiriou M, Galesic K, Toric L, Papagianni A, Stangou M, Benozzi L, Cusinato S, Berg U, Topaloglu R, Maggio M, Ots-Rosenberg M, D'Amico M, Geddes C, Balafa O, Quaglia M, Cravero R, Lino Cirami C, Fellstrom B, Floege J, Egido J, Mallamaci F, Zoccali C.

Nephrol Dial Transplant. 2018 Nov 9. doi: 10.1093/ndt/gfy302. [Epub ahead of print]

PMID:
30418652
44.

Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease.

Scheppach JB, Raff U, Toncar S, Ritter C, Klink T, Störk S, Wanner C, Schlieper G, Saritas T, Reinartz SD, Floege J, Janka R, Uder M, Schmieder RE, Eckardt KU, Schneider MP.

Hypertension. 2018 Oct;72(4):929-936. doi: 10.1161/HYPERTENSIONAHA.118.11608.

PMID:
30354716
45.

Urinary Biomarkers in the Prediction of Prognosis and Treatment Response in IgA Nephropathy.

Neuhaus J, Bauer F, Fitzner C, Hilgers RD, Seibert F, Babel N, Doevelaar A, Eitner F, Floege J, Rauen T, Westhoff TH.

Kidney Blood Press Res. 2018;43(5):1563-1572. doi: 10.1159/000494442. Epub 2018 Oct 22.

46.

Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss.

Zewinger S, Rauen T, Rudnicki M, Federico G, Wagner M, Triem S, Schunk SJ, Petrakis I, Schmit D, Wagenpfeil S, Heine GH, Mayer G, Floege J, Fliser D, Gröne HJ, Speer T.

J Am Soc Nephrol. 2018 Nov;29(11):2722-2733. doi: 10.1681/ASN.2018040405. Epub 2018 Oct 2.

47.

[What is certain in the treatment of glomerulonephritis?]

Floege J, Boor P, Moeller MJ.

Internist (Berl). 2018 Dec;59(12):1268-1278. doi: 10.1007/s00108-018-0500-8. Review. German.

PMID:
30250965
48.

Magnesium Concentration in Dialysate: Is Higher Better?

Floege J.

Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1309-1310. doi: 10.2215/CJN.08380718. Epub 2018 Aug 21. No abstract available.

49.

YB-1 increases glomerular, but decreases interstitial fibrosis in CNI-induced nephropathy.

Gibbert L, Hermert D, Wang J, M Breitkopf D, Alidousty C, Neusser M, Cohen CD, Gröne E, Macheleidt I, Rauen T, Braun GS, Floege J, Ostendorf T, Raffetseder U.

Clin Immunol. 2018 Sep;194:67-74. doi: 10.1016/j.clim.2018.07.002. Epub 2018 Jul 3.

PMID:
30018024
50.

Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.

Sprague SM, Floege J.

Expert Opin Pharmacother. 2018 Jul;19(10):1137-1148. doi: 10.1080/14656566.2018.1491548. Epub 2018 Jul 9. Review.

PMID:
29985725

Supplemental Content

Loading ...
Support Center